| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Hypertension. 2008;52:10.)
© 2008 American Heart Association, Inc.
AHA/ASH/PCNA Scientific Statements |
| Abstract |
|---|
12 readings are recommended for making clinical decisions; (4) HBPM is indicated in patients with newly diagnosed or suspected hypertension, in whom it may distinguish between white-coat and sustained hypertension. If the results are equivocal, ambulatory BP monitoring may help to establish the diagnosis; (5) In patients with prehypertension, HBPM may be useful for detecting masked hypertension; (6) HBPM is recommended for evaluating the response to any type of antihypertensive treatment and may improve adherence; (7) The target HBPM goal for treatment is <135/85 mm Hg or <130/80 mm Hg in high-risk patients; (8) HBPM is useful in the elderly, in whom both BP variability and the white-coat effect are increased; (9) HBPM is of value in patients with diabetes, in whom tight BP control is of paramount importance; (10) Other populations in whom HBPM may be beneficial include pregnant women, children, and patients with kidney disease; and (11) HBPM has the potential to improve the quality of care while reducing costs and should be reimbursed. (Hypertension. 2008;52:10-29.)
Key Words: AHA Scientific Statements blood pressure hypertension patients
| Introduction |
|---|
Of the 2 methods, HBPM has the greatest potential for being incorporated into the routine care of hypertensive patients in the same way that home blood glucose monitoring performed by the patient has become a routine part of the management of diabetes. The currently available monitors are relatively reliable, easy to use, inexpensive, and accurate and are already being purchased in large numbers by patients. Despite this, their use has been only cursorily endorsed in current guidelines for the management of hypertension, and there have been no detailed recommendations in regard to the manner in which they should be incorporated into routine clinical practice. In addition, despite the fact that there is strong evidence that HBPM can predict clinical outcomes and improve clinical care, the cost of the monitors is not generally reimbursed. It is the purpose of this call-to-action article to address the issues of the incorporation of HBPM into the routine management of hypertensive patients and its reimbursement.
| Health and Economic Consequences of Hypertension and Its Inadequate Control in the United States |
|---|
140 mm Hg or a diastolic BP of
90 mm Hg, taking BP-lowering medications, or being told at least twice by a physician or other health professional that they had high BP.1 This estimate may be considered conservative because it does not include the additional persons with systolic BP of
130 mm Hg or diastolic BP of
80 mm Hg with either diabetes mellitus or chronic kidney disease who would be classified as having high BP according to the definition put forward by the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7).2 Worldwide estimates approach 1 billion people with high BP.3 High BP increases the risk of total mortality; mortality due to heart disease, stroke, chronic kidney disease, and heart failure; and morbidity associated with nonfatal cardiovascular disease (CVD) events.2 On the basis of estimates of population-attributable fractions, high BP may account for 27% of total CVD events in women and 37% in men,4 14% of myocardial infarctions in men and 30% in women,5 35% of ischemic strokes,6 39% of chronic heart failure events in men and 59% in women,7 and 56% of chronic kidney disease.8 These results, based on North American populations, are supported by global estimates. In the Global Burden of Disease Project, a systolic BP threshold of 115 mm Hg was used to distinguish between optimal and nonoptimal BP levels. Globally, 62% of stroke, 49% of coronary heart disease, and 14% of other CVD was attributable to nonoptimal BP. Approximately 12.8% of all deaths (7.1 million) and 4.4% of all disability life-years lost (64.3 million) in the year 2000 were due to CVD attributable to nonoptimal BP levels.9 Clearly, high BP is a major cause of mortality and morbidity in the United States and worldwide.
Randomized controlled trials have provided convincing evidence that BP-lowering treatment reduces the risk of total mortality, stroke, coronary heart disease, heart failure, and chronic kidney disease.2 Consequently, clinical practice guidelines have been promulgated in the United States and elsewhere to promote detection, treatment, and control of high BP.2 Despite 30 years of attention to high BP control in the United States, current levels of control are suboptimal. On the basis of data from NHANES 2003–2004, 76% of persons with high BP had been told that their BP was high, 65% were on treatment with BP-lowering medications, and only 37% were controlled to BP levels <140 mm Hg systolic and <90 mm Hg diastolic.10 These proportions mask ethnic disparities. The proportion aware of having high BP was 67% among non-Hispanic whites, 66% among non-Hispanic blacks, and 63% among Mexican Americans. The proportion on treatment varied from 55% among non-Hispanic blacks, to 54% among non-Hispanic whites, and 48% among Mexican Americans. The proportion with controlled BP was highest in non-Hispanic whites (35%), intermediate in non-Hispanic blacks (29%), and lowest in Mexican Americans (26%).10
The direct and indirect cost of high BP and its complications was estimated to be $63.5 billion in the United States in 2006.11 This figure is almost certainly an underestimation of the true costs of the complications of high BP because, in this analysis, the cost attributable to hypertensive disease was distinguished from the costs attributed to coronary heart disease ($142.5 billion), stroke ($57.9 billion), and chronic heart failure ($29.6 billion),11 and, as documented above, high BP is a major contributor to these forms of CVD. Given the substantial mortality, morbidity, and cost associated with poorly controlled BP in the United States and other countries, identification of low-cost strategies to improve control of high BP should be a high priority.
| Recommendations of Professional Organizations on the Use of HBPM |
|---|
| Current Usage of HBPM |
|---|
A recently published survey of 855 hypertensive patients attending specialized clinics in Italy found that 75% were regularly performing HBPM.20 Users tended to be younger and better educated than nonusers; 58% used electronic devices that recorded from the upper arms, and 19% used wrist monitors.
Physicians are also becoming enthusiastic about the use of HBPM. A survey of family practitioners in Hungary found that 90% recommended the use of HBPM.21 The physicians main concerns were the use of nonvalidated devices, the possibility that patients would become obsessive about their BP, and the lack of proper training in the use of the monitors. A survey of pediatric nephrologists in Germany found that 70% prescribed the use of HBPM for children with renal disease and hypertension.22
| Techniques for Performing HBPM |
|---|
Arm Monitors
Monitors that measure the BP in the brachial artery with a cuff placed on the upper arm continue to be the most reliable and have the additional advantage that the brachial artery pressure is the measure that has been used in all the epidemiological studies of high BP and its consequences. For the majority of patients, this is the preferred type of monitor.
Wrist Monitors
Wrist monitors are the most convenient type to use and are preferred by many patients. They have the potential advantage that they can be used in obese individuals in whom putting a cuff on the upper arm is difficult. A potential disadvantage is that the wrist must be held at the level of the heart when a reading is being taken, which increases the possibility of erroneous readings.24 A recently introduced model avoids this problem by taking readings only when the wrist is held over the heart. Experience with wrist monitors is relatively limited at present, and most of the monitors that have been tested have failed the validation studies (see http://www.dableducational.org). They are therefore not generally recommended for routine clinical use.
Finger Monitors
These devices have been found to be very inaccurate and should not be used.25
Testing and Validation of Monitors
Patients should be advised to use only monitors that have been validated for accuracy and reliability according to standard international testing protocols. The original 2 protocols that gained the widest acceptance were developed in the United States by the Association for the Advancement of Medical Instrumentation in 1987 and the British Hypertension Society in 1990, with revisions to both in 1993. These required testing of a device against 2 trained human observers in 85 subjects, which made validation studies difficult to perform. One consequence of this has been that there are still many devices on the market that have never been validated adequately. More recently, an international group of experts who are members of the European Society of Hypertension Working Group on Blood Pressure Monitoring have produced an international protocol that is replacing the 2 earlier versions26 and is easier to perform. Briefly, it requires comparison of the device readings (4 in all) alternating with 5 mercury readings taken by 2 trained observers in 33 patients. Devices are recommended for approval if both systolic and diastolic readings taken are within at least 5 mm Hg of each other for at least 2 of each subjects 3 readings in 22 of the 33 subjects.
Unfortunately, only a few of the devices that are currently on the market have been subjected to proper validation tests such as the Association for the Advancement of Medical Instrumentation and British Hypertension Society protocols, and several devices have failed the tests. An up-to-date list of validated monitors is available on the Dabl Educational Web site (http://www.dableducational.org) and the British Hypertension Society Web site (http://www.bhsoc.org/default.stm).
The fact that a device passed a validation test does not mean that it will provide accurate readings in all patients. There can be substantial numbers of individual subjects in whom the error is consistently >5 mm Hg with a device that has achieved a passing grade.27 This may be more likely to occur in elderly28 or diabetic patients.29 At least 1 home monitor has been found to be accurate in patients with end-stage renal disease.30 For this reason, it is recommended that each oscillometric monitor should be validated on each patient before the readings are accepted. No formal protocol has yet been endorsed for doing this, but if sequential readings are taken with a mercury sphygmomanometer and the device as described below, major inaccuracies can be detected.
Checking Monitors for Accuracy
When patients get their own monitor, it is very important to have them bring it into the clinic to check their technique as well as the accuracy of the monitor. A simple and practical version of the European Society of Hypertension Protocol has been developed for this purpose and can be done in <10 minutes by the physician or other healthcare provider and the patient. The patient sits at the physicians desk with the monitor set up and the arm resting on the desk. Five sequential same-arm BP readings are recorded with a gap of no more than
30 seconds between readings. The first 2 (D1 and D2) are taken by the patient using the patients device; the third (M1) by the physician using a mercury sphygmomanometer; the fourth (D3) by the patient; and the fifth (M2) by the physician. There is a tendency for the BP to decline during this process (Figure 1). The accuracy of the device can be assessed by comparing the device and mercury readings, although exact criteria for determining acceptability have not been established.
|
| Patient Education |
|---|
Once a monitor has been purchased, it is recommended that the patient should bring it into the office to verify both the patients technique and the accuracy of the device. This procedure should be repeated annually. Unlike aneroid and mercury devices, however, it has been found that the accuracy of the measurement of the cuff pressure does not deteriorate over time with oscillometric monitors.33
| Contraindications to HBPM |
|---|
Some patients may become obsessed about taking readings. The inherent variability of BP means that there will inevitably be some high readings, which in anxious patients may exacerbate their anxiety, leading to further increases of BP and effectively setting up a vicious cycle. In such patients frequent checking of their BP should be discouraged, and in extreme cases it should be discontinued altogether.
| Information Provided by HBPM |
|---|
HBPM as an alternative to the office BP reading can no longer be overlooked as a significant adjunct to assessment and treatment of individuals with hypertension. The following paragraphs will review data about the quality and type of increased information that HBPM can provide healthcare providers.
Information Is Reliable and Reproducible
One of the advantages of HBPM is that large numbers of readings can be used to define a patients BP level. Stergiou et al44 compared the reproducibility of BP measured in the office (5 visits within 3 months), in the home (6 workdays within 2 weeks), and by ABPM (twice, 2 weeks apart). Reproducibility was quantified with the use of the standard deviation of the differences between repeated measurements. The researchers found that home BP readings provided the lowest standard deviation of the differences (6.9/4.7 mm Hg for systolic and diastolic pressures) compared with clinic (11.0/6.6 mm Hg) and ambulatory pressures (8.3/5.6 mm Hg) and therefore had superior reproducibility. Home readings may be more stable than ABPM readings because the conditions in which they are taken are less variable.
Long-term reproducibility was examined in a sample of 136 untreated subjects who measured their BP at home at least 3 times on at least 3 days in each of two 4-week periods separated by 1 year.45 Two clinic BPs were also obtained from subjects at each of 2 health examinations also separated by 1 year. The mean differences between the first and second home BP readings (0.8±7.7 mm Hg for systolic BP and 0.9±5.5 mm Hg for diastolic BP) were significantly smaller than those for the clinic BP (–3.9±13.8 mm Hg for systolic BP and –3.1±10.2 for diastolic BP) (P<0.001 for both comparisons). These findings suggest that home BP measurements are more reproducible over time than office BP measurements.
Another aspect of the reliability of HBPM is the accuracy of patients in reporting the readings displayed by the monitors. This issue has been examined by providing patients with monitors that, unknown to the patients, have memory. When patients reported readings are compared with those stored in the memory, it has been found that there is often poor agreement between them. In 1 study, 20% of readings were reported with an error of >10 mm Hg, and the error rate was higher in patients with less well controlled hypertension.46 In another there was a consistent tendency for high readings to be underreported.47 Thus, patients may tend to make their home readings look better than they really are, and for this reason monitors with memory are to be encouraged.
Number of Home BP Measurements Needed to Ensure a Reliable Estimate of True BP
The reproducibility of home BP measurements is heavily dependent on the number of measurements that are averaged. One study demonstrated that the maximal reduction in the standard deviation of the mean difference between the average values of 2 HBPM sessions is obtained when the average value is based on
30 readings (3 measurements per day for 10 days).48 Others have suggested that no further improvement is obtained by increasing the number >549 and that improvement in measurement precision is obtained with
6 home measurements.50,51
There is some agreement that correlations with ambulatory BP are more reliable if the first days home BP readings are discarded.52,53 Two recent analyses have recommended taking between 8 and 15 readings in total,53,54 and we recommend following the last set of European Society of Hypertension guidelines to take
2 morning and 2 evening readings every day for 1 week16 but to discard the readings of the first day, which gives a total of 12 readings on which to make clinical decisions. Getting multiple readings is particularly important for the initial diagnosis of hypertension, but the same procedure is also recommended to be performed at intervals in patients whose condition is thought to be stable and who require long-term follow-up. Patients should be instructed to record all the readings that they take.
Information About True BP Level
BP fluctuates continuously in a 24-hour period, and the variability is influenced by neural, mechanical, and humoral factors.55,56 Patient-related factors, for example, hurrying to get to a clinic visit or impatience over waiting to be seen, are also associated with BP variability. BP readings in the office tend to reflect the patients status at the moment and may not be a true representation of the BP outside the office.57 It is difficult to determine true BP level on the basis of 1 or 2 BP measurements at the time of an office visit. HBPM is a simple and inexpensive way to obtain a large number of readings, representative of usual BPs over long periods of time, that are unaffected by the white-coat effect (the increase of BP that occurs during an office visit) or other factors influencing variability that are present in the office.58 Patterns of BP rather than isolated measurements can be important in confirming the diagnosis of hypertension. For patients found to be hypertensive in the office, high BPs measured at home may confirm the diagnosis, whereas low home BP levels may indicate a need for further assessment with ambulatory BP measurement for identification of white-coat hypertension.59
A recent development in the measurement of clinic BP is the introduction of automated oscillometric devices that can take multiple (2 to 6) readings in the clinic in the absence of a physician. They have the potential advantage over traditional clinic measurement in that they reduce the white-coat effect (hence, they are consistently lower than physicians readings)60 and are closer to the daytime average measured with ABPM.61 Data are lacking for comparisons with HBPM.
Another technique that has been used by patients to monitor their BP out of the office is the use of automated devices in malls and supermarkets. These devices may be inaccurate, and their use is not encouraged.
Information About BP at Different Times of the Day
The pattern of BP change over the day may vary considerably from one patient to another, depending on their daily routine. Thus, in Japanese studies, the evening pressure tends to be lower than in the morning, which has been related to the fact that Japanese people often take baths in the evenings, after which the BP is reduced.62 Other studies have found that evening readings are higher.63,64 The morning pressure may be higher if the patient has drunk alcohol the night before65 or has sleep apnea.66 Antihypertensive treatment may also have a major influence.67 There is some evidence that the morning pressure may be a better predictor of risk than the evening pressure.68,69 For these reasons, it is generally recommended that patients should take readings both in the early morning and at night. The main limitation of home monitors in comparison with 24-hour ambulatory monitors is that nighttime readings cannot be taken. However, monitors are being developed that can be programmed to take a limited number of readings during the night.
| HBPM for Diagnosing Hypertension |
|---|
10% of patients it may be higher, indicating a possible diagnosis of masked hypertension.70 As described below, there is increasing evidence that home BP may provide a better prediction of risk than office BP, and therefore any discrepancies between office and home BP should be taken seriously.
Evaluation of White-Coat Hypertension and White-Coat Effect
National hypertension guideline committees from the United States,2 Europe,16 Canada,16,71 and Japan17 have all endorsed the use of HBPM to confirm or refute the diagnosis of white-coat hypertension, which is defined as high BP occurring only in a medical care setting and that has been reported in as many as 20% of patients in whom hypertension has been diagnosed by office BP.72–74 The phenomenon that leads to it is called the white-coat effect, which is usually defined as the difference between the office BP and the BP measured at home or during the day by ABPM, and which has been attributed to anxiety, a hyperactive alerting response, or a conditioned response.42 The white-coat effect is typically positive and is present in the majority of hypertensive patients, but in some patients with low office BP it may be negative (home BP higher than office BP). If the home BP is normal (<135/85 mm Hg), a diagnosis of white-coat hypertension may be considered.
White-coat hypertension is more common in the elderly and is generally associated with a relatively benign prognosis similar to that seen in truly normotensive subjects, as shown by several prognostic studies comparing office BP and ambulatory BP.75,76 However, with longer-term follow-up (eg, 6 to 11 years), there have been reports of higher CVD event rates that are similar to those seen in patients with sustained hypertension.77,78 The implication of these results is that out-of-office monitoring (HBPM and/or ABPM) should be conducted long term in all patients diagnosed with white-coat hypertension.
White-coat hypertension cannot be diagnosed reliably on clinical examination alone. The average BP levels obtained by multiple home readings and those recorded by ABPM while the patient is awake are very close, and both are lower than BPs measured in the office.37 In a study of 247 untreated hypertensive patients, investigators examined the extent to which HBPM can be an alternative to ABPM to diagnose white-coat hypertension. Using ABPM as a reference, they found that the specificity of HBPM to detect white-coat hypertension was 88.6%, and the sensitivity was 68.4%.79 Although home BPs may not be completely without white-coat effects,80 they may serve better as a screen for white-coat hypertension than for the final diagnosis. The Ohasama study was the first to show the superior predictive value of home BP over office BP, such that patients with white-coat hypertension were at relatively low risk.81 The Pressioni Arteriose Monitorate e Loro Associazioni (PAMELA) study evaluated prognosis with office, home, and ambulatory BP over an 11-year follow-up.78 Although they found that patients with high office BP and normal home BP or ambulatory BP (ie, white-coat hypertension) were at increased risk, the thresholds were different. Thus, the systolic BP level that would confer a risk of cardiovascular death over an 11-year period of 10% was 179 mm Hg for office BP, 163 mm Hg for home BP, and 157 mm Hg for daytime ambulatory BP.82 This is consistent with the recommendation that a lower cutoff level should be used for home BP than for office BP.
Algorithm for Use of HBPM in Clinical Practice
An algorithm that uses both HBPM as an initial screening test and ABPM to make the definitive diagnosis has been proposed by a panel of the American Society of Hypertension13 and by the First International Consensus Conference for Self-Blood Pressure Monitoring,83 as shown in a modified version in Figure 2. The rationale for this is that the exclusive reliance on office BP for making therapeutic decisions may lead to both undertreatment and overtreatment in individual patients because of both the inherent variability of BP and the white-coat effect. As originally proposed, this algorithm would be applied only to patients who have a persistently high office BP (>140/90 mm Hg), but it might also be applicable to those with high-normal BP (eg, a patient who has had some readings >140/90 mm Hg but on rechecking has a slightly lower level), in whom masked hypertension may be suspected. In addition, in patients with diabetes or kidney disease, it may be used if the office BP is
130/80 mm Hg. In patients who have evidence of target organ damage that is thought to be the result of hypertension, it may be decided to start treatment on the basis of the high office BP, although HBPM is still valuable for monitoring the response to treatment. The rationale here is that numerous studies have shown that even subclinical markers of organ damage such as microalbuminuria or left ventricular hypertrophy have been shown to increase CVD risk, as reviewed in the recent European guidelines on the management of hypertension,84 which may justify more aggressive treatment.
|
In those in whom the decision to start treatment remains unclear, HBPM is an appropriate next step, with the goal of obtaining a minimum of 12 readings taken both in the morning and at night over a period of 7 days. If the average value is >135/85 mm Hg, there is a high probability (85%) that the ambulatory BP will also be high,85 and a decision to start treatment can be made. If the home BP is <125/76 mm Hg, the probability of missing a diagnosis of true hypertension is quite low.85 Because BP varies with time, whichever method of measurement is used, a diagnosis of white-coat hypertension is not cast in stone, and all patients in whom the diagnosis is made require long-term monitoring of BP, for which HBPM is ideally suited.
Evaluation of Masked Hypertension
HBPM may also be useful in detecting masked hypertension, also known as reverse white-coat hypertension or isolated home or isolated ambulatory hypertension. Masked hypertension occurs when a patients office BP is <140/90 mm Hg but ambulatory or home readings are in the hypertensive range (typically >135/85 mm Hg).86 It conveys the same cardiovascular risk as sustained hypertension, and therefore it is important that it is detected.87,88
The prevalence of masked hypertension may be
10% in the general population,81,87,89 but at the present time there is no consensus in regard to how it should be detected or treated in people who have not been diagnosed as hypertensive. However, in patients with treated hypertension that is thought to be well controlled (ie, an office BP <140/90 mm Hg), it may be equally common. In the Self-Measurement of Blood Pressure at Home in the Elderly: Assessment and Follow-up study (SHEAF) of 4939 elderly treated hypertensive patients being followed in family practices in France, the prevalence of masked hypertension (defined by an office BP <140/90 plus home BP >135/85 mm Hg) was 42% of the patients with a normal office BP.87 In a descriptive study of 438 Turkish patients receiving care in an internal medicine clinic, all patients had their BP measured in the office, by 24-hour ABPM, and by HBPM twice a day for 10 days.90 The prevalence of masked hypertension was <5% until the seventh decade of life, and it was 7.6% in the seventh and 16.6% in the eighth decade of life. There were no significant differences in the prevalence of masked hypertension depending on whether ambulatory or home BPs were used to define it. In the Japan Home versus Office BP Measurement Evaluation (J-HOME) study91 of treated hypertensive patients in Japan, >50% of patients with controlled office BP had masked hypertension (home BP >135/85 mm Hg). These patients tended to be older and were more likely to have a past history of coronary heart disease or chronic kidney disease. This high prevalence in patients whose BP appears to be controlled by conventional clinical criteria makes the case that HBPM should be used routinely in treated hypertensive patients.
Evaluation of Prehypertension
Approximately 28% of American adults, or 59 million people, have prehypertension, defined as BP in the range of 120 to 139/80 to 89 mm Hg.2,11 Because this is normally diagnosed by office BP, some will have white-coat hypertension. Regular and consistent monitoring of BP should begin during prehypertension to establish the need for treatment or help to establish a firm baseline for determining response and change. Limited information is available on the use of HBPM in this situation, but it is ideally suited to these needs. One study (the Tecumseh study) found that in prehypertensive individuals (n=735) diagnosed by office readings, home BP (average of 14 readings, 7 days with morning and afternoon or evening readings) was more predictive than office BP of future BP status after 3 years, even when the same number of measurements was used for both methods.92
Evaluation of Resistant Hypertension
HBPM may be helpful for evaluating resistant hypertension in patients exhibiting high office BP under antihypertensive therapy. Patients who appear to be refractory to treatment in the office may have adequately controlled home BP93 and consequently may require less intensification of drug treatment than those whose home BP is also high.
| HBPM for Predicting Cardiovascular Risk |
|---|
Several other cross-sectional studies have shown that BP measured at home correlates with hypertensive target organ damage. Kleinert et al23 found that the degree of left ventricular hypertrophy determined by echocardiography was more strongly correlated to multiple self-measurements than to office BP. Abe et al95 found that the correlation between BP levels and target organ damage for self-measured readings at home and office readings was similar. Hypertensive complications were equally related to home and office BPs.95 Jula et al96 compared multiple office and home BP and ambulatory BP measurements in the clinical evaluation of hypertension using a sample of 239 untreated hypertensive adults. They found that office and home BPs predicted albuminuria and left ventricular hypertrophy at least equally to ABPM. Left ventricular mass index correlated slightly more strongly with morning home systolic BP/diastolic BP than evening readings (r=0.46/0.43, P<0.001 and r=0.41/0.37, P<0.001 for morning and evening BPs).
Other investigators have used cross-sectional designs to evaluate the usefulness of HBPM in diabetics. Researchers examined whether BP elevations in the morning detected by HBPM were more predictive than office BP for microvascular (nephropathy and retinopathy) and macrovascular complications (coronary heart disease and cerebral vascular disease) in type 2 and type 1 diabetic patients.69,97 In both groups, home BP but not office BP was strongly related to nephropathy. There were no significant differences between the groups for the other measures of target organ damage.
Five prospective studies (all with several publications) have compared the prediction of morbid events with the use of both conventional office BP and home BP (Table 1).99,100 Three were based on population samples, and 2 recruited hypertensive patients. Four studies found that home BP was the stronger predictor of risk. The fifth (Didima) reported that both home BP and office BP predicted risk equally well.98
|
The first was the population-based Ohasama study, which was conducted in 1789 subjects aged >40 years who were followed for a mean of 6.6 years.81 Subjects were asked to measure their BP at home within 1 hour of waking over a 4-week period. The mean number of measures recorded was 20.8±8.3. As part of annual screening visits, 2 consecutive measures of BP were recorded by a nurse or technician after 2 minutes of rest. When HBPM and BPs taken during annual screening were included in a Cox regression model, only home systolic BPs were significantly related to cardiovascular mortality risk (multiple home systolic BP relative hazard=1.012, P=0.048; screening systolic BP relative hazard=1.000, P=0.972; multiple diastolic BP relative hazard=1.013, P=0.414; screening diastolic BP relative hazard=1.006, P=0.642). Moreover, the average of 2 home BP measures showed a stronger relationship to mortality than the screening BPs taken by nurses and technicians.
More recently, the Ohasama data have been examined to determine the predictive value of HBPM on the risk of transient ischemic attack and hemorrhagic and ischemic stroke.101 Of the 1789 patients in the original study, mean duration of follow-up was 10.6 years. Home BP values were linearly related to risks for total, hemorrhagic, and ischemic stroke. A 10-mm Hg elevation in home systolic BP was associated with 29%, 32%, and 30% increases in the risk of total, hemorrhagic, and ischemic strokes, respectively. Finally, home BP values showed a significantly greater relation to the risk of both hemorrhagic and ischemic stroke than screening BP values (P<0.02). In another analysis, Ohkubo and colleagues102 found that the predictive value of stroke risk increased for all measures of home BP but was greatest when at least 14 measurements were obtained. The original reports were based on readings taken in the morning, but a later analysis included evening readings and found that both measures predicted strokes, but morning readings were superior in patients taking antihypertensive medications.68 The Ohasama study also included ABPM and has reported that the average BP during the first 2 hours after waking is an independent predictor of risk.103 These findings emphasize the importance of taking BP readings early in the morning.
The second prospective study was the SHEAF study, a 3-year prospective cohort study designed to determine the prognostic value of HBPM compared with office measures in an older population (>60 years) with hypertension seen in general practice settings in France.99 Treated patients with hypertension were followed in 2 phases: Phase 1 included an evaluation of office and home BP over 1 month, and phase 2 included a 3-year observational phase without specific recommendations with regard to the management of hypertension. Phase 1 office measures included triplicate measures on each of 2 visits. HBPM was done over a 4-day period with 3 consecutive measurements taken in the morning and repeated in the evening. At the end of follow-up, neither method of measurement was significantly related to CVD events or mortality. However, with the use of a Cox model to control for predictors such as age, CVD history, and smoking status, HBPM was predictive of cardiovascular events. Each 10-mm Hg increment of systolic BP measured at home increased the risk of a cardiovascular event by 17.2%, and each 5-mm Hg increase in diastolic BP increased the risk by 11.7%. Conversely, when the model was applied to office measures controlling for the same predictors, there was no significant increase in CVD events. In patients with masked hypertension (ie, normal office but raised home BP, who comprised 9% of the total sample), the risk was increased (hazard ratio, 2.06) and much higher than in patients with high office and normal home BP (hazard ratio, 1.18).
The third study was PAMELA, a population-based survey of 2051 Italian subjects who were evaluated with HBPM (2 readings: 1 in the morning and 1 in the evening), office BP (3 readings taken with a sphygmomanometer on each of 2 visits), and ABPM.82 Approximately half of the subjects were hypertensive. Over a 10-year follow-up, there were 186 deaths. All 3 measures of BP predicted mortality. The steepest association between BP and outcomes was with the nighttime BP, but this may be attributed to the fact that nighttime BP shows much less variation than other measures. The goodness of fit, which is a better measure of the strength of the relationship, was strongest for the home BP. In a subsequent publication,78 it was reported that elevation of any of the 3 measures of BP was associated with increased risk. Thus, a high home BP should not be ignored, even if other measures are normal.
The fourth study was conducted in Belgium and compared the prognostic significance of office and home BP, both measured by a physician (who visited the patients homes), and ambulatory BP in a sample of 391 adults
60 years of age who were being seen in a primary care setting.100 Home and office examinations were performed within 2 weeks of one another. Health outcomes (ie, aggregate of stroke, myocardial infarction, and cardiovascular death) were determined after a median follow-up of 10.9 years. Home BP and daytime and nighttime ambulatory BP predicted cardiovascular events, independent of office BP. BP measured by the primary care physician in the office was not independently predictive of future cardiovascular events. Diastolic but not systolic home BP added prognostic precision to daytime and nighttime ambulatory BP. In sum, the prognostic value of BP measured in the patients home was at least equal to that of daytime ambulatory BP. This study is of particular interest because it suggests that the relatively poor predictive value of office BP in comparison with home BP is not because of the confounding effects of the physician but rather because of the medical setting itself.
The fifth study is a long-term (8.2 years) follow-up of 662 subjects in the Didima Study,98 which is a population-based study of the inhabitants of Didima, a village in Greece. The average age was 54 years, and hypertension was diagnosed in 28%, of whom 55% were on antihypertensive drug treatment. Office BP was evaluated on 2 days (3 readings each day) by the village family physician. Home BP was taken as duplicate readings morning and evening for 3 days. The main finding was that both the office and the home BP predicted CVD events, but neither was clearly superior. After adjustment for age and gender, the hazard ratio for a 1-mm Hg increase of systolic BP was 1.016 (CI, 1.004 to 1.029; P=0.01) for home BP and 1.021 (CI, 1.009 to 1.034; P=0.001) for office BP. When fully adjusted (including history of CVD, antihypertensive treatment, diabetes, and smoking), neither measure of systolic BP predicted events. For diastolic pressure, the office BP was superior to the home BP and was the only measure to predict events after fully adjusting for covariates (hazard ratio, 1.034; CI, 1.008 to 1.061; P=0.01). The authors concluded that the CIs were too wide to draw firm conclusions about the relative importance of the 2 methods for predicting risk.
A sixth study performed in Kahoku, a rural town in Japan, on 1186 elderly people (mean age, 74 years) reported a U-shaped relationship between home BP and mortality (evaluated from death certificates).104 There was no comparison with office BP, however, and therefore it is not included in the table.
Three longitudinal studies have examined the ability of HBPM to predict the progression of renal disease. One found that systolic home BP was a stronger predictor of end-stage renal disease and death than office BP among 217 veterans with chronic kidney disease who had a median follow-up of 3.5 years.105 The second followed 77 patients with diabetes for 6 years and concluded that home BP was a better predictor of progression of diabetic nephropathy than office BP measurements.106 The third used a sample of 113 hypertensive patients with nondiabetic chronic kidney disease who were followed for 3 years and found that home BP measured in the morning was a better predictor of the decline in glomerular filtration rate.107
These studies thus present a very consistent picture showing that HBPM can give a better prediction of cardiovascular risk than office BP (class IIa; level of evidence A).
Information About BP Control
HBPM has the ability to provide information about BP control outside the office setting. Using data (n=3400) from the J-HOME study, investigators examined the characteristics of BP control based on home and office measurement.108 Although 42% of the sample had their BP controlled by office BP criteria (<140/90 mm Hg), only 34% also had home BP control (<135/85 mm Hg). Other investigators have also demonstrated the value of HBPM in determining BP control outside the office.109–111 The SHEAF study described above found that the 9% of patients with normal office BP but elevated home BP (ie, masked hypertension) had twice the risk of CVD events as the group in whom both office and home BP were controlled.99
| Use of HBPM to Guide and Evaluate Treatment |
|---|
|
|
|---|